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Abdominal surgery and disease cause persistent abdominal adhesions, pelvic pain, infertil-
ity and occasionally, bowel obstruction. Current treatments are ineffective and the aetiology
is unclear, although excessive collagen deposition is a consistent feature. Lysyl oxidase
(Lox) is a key enzyme required for crosslinking and deposition of insoluble collagen, so we
investigated whether targeting Lox might be an approach to reduce abdominal adhesions.
Methods
Female C57Bl/6 mice were treated intraperitoneally with multiwalled carbon nanotubes (NT)
to induce fibrosis, together with chemical (ß-aminoproprionitrile–BAPN) or miRNA Lox inhib-
itors, progesterone or dexamethasone. Fibrotic lesions on the diaphragm, and expression of
fibrosis-related genes in abdominal wall peritoneal mesothelial cells (PMC) were measured.
Effects of BAPN and dexamethasone on collagen fibre alignment were observed by TEM.
Isolated PMC were cultured with interleukin-1 alpha (IL-1α) and progesterone to determine
effects on Lox mRNA in vitro.
Results
NT-induced fibrosis and collagen deposition on the diaphragm was ameliorated by BAPN,
Lox miRNA, or steroids. BAPN and dexamethasone disrupted collagen fibres. NT increased
PMC Lox, Col1a1, Col3a1 and Bmp1 mRNA, which was inhibited by steroids. Progesterone
significantly inhibited IL-1α induced Lox expression by PMC in vitro.
Conclusion
Our results provide proof-of-concept that targeting peritoneal Lox could be an effective
approach in ameliorating fibrosis and adhesion development.
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Introduction
Aberrant peritoneal fibrosis leading to adhesion formation is a feature of abdominal surgery,
infection or disease, resulting in abdominal pain, infertility and, in severe cases, bowel obstruc-
tion. Adhesions are also a common feature of endometriosis [1]. Recent reviews [2,3] summa-
rized a range of anti-adhesive barrier and pharmacological measures that have been used to
prevent abdominal adhesions. No single adhesion-preventative measure has emerged as
unequivocally effective, although randomized controlled trials provide supporting evidence
for the use of most barrier/gel agents, and post-operative corticosteroids remain the only likely
pharmacological contender [2–4], but even so, the effectiveness of glucocorticoids is contro-
versial [3,5,6]. Fibrosis is a prominent feature of the peritoneum in dialysis patients, and gluco-
corticoids have been implicated as a potential treatment to reduce fibrosis and the onset of the
life-threatening condition of encapsulating peritoneal sclerosis [7].
The precise aetiology of adhesion formation is unclear, but is likely due to excessive colla-
gen deposition resulting from incomplete fibrinolysis at the site of injury/damage to the perito-
neal mesothelial cells (PMC) [8]. A key step in collagen deposition requires cross-linking of
collagen to form an insoluble matrix, controlled by the copper dependent amine oxidase, lysyl
oxidase (Lox) [9]. Lox has been implicated in mouse models of dermal wound healing [10]
and scarring [11] as well as fibrosis [12]. LOX mRNA increased in rabbit abdominal wall scars
[13], and over 30 years ago the lathryogen ß-aminopropionitrile (BAPN), which irreversibly
inhibits LOX activity, was found to inhibit skin collagen polymerisation and scarring in rats
[14].
Regulation of LOX mRNA and enzyme activity has been noted in rat ovarian granulosa
cells [15] and also in human ovarian surface epithelial cells (OSE) [16]. IL-1α enhanced and
cortisol inhibited LOX mRNA expression in human OSE cells [16]. Lox mRNA also increased
in the parietal peritoneum and PMC of a chlorhexidine gluconate-induced peritoneal fibrosis
mouse model [17]. Upregulation of LOX has also recently been implicated in abnormal endo-
metrial function and in proliferation, migration and invasion of endometriotic lesions [18]
In this study, we chose a mouse model of carbon nanotube (NT)-induced fibrosis on the
abdominal surface of the diaphragm [19] to investigate the role of Lox in mediating the fibrotic
response. We showed that NT-induced fibrosis was accompanied by increased lox expression
in PMC, and that chemical or miRNA mediated inhibition of Lox reduced the fibrotic
response. Additionally, we assessed if glucocorticoid and/or progesterone was able to amelio-
rate the fibrotic response, with the aim of re-examining the role of glucocorticoids and sex ste-
roids, and exploring the mechanism of local steroid action in fibrosis and adhesion formation
in the peritoneal cavity. To study the effects of inflammatory and anti-inflammatory factors on
the expression of fibrosis-related genes, we collected PMCs from the abdominal wall to deter-
mine mRNA expression, and also measured mRNA expression after culturing abdominal wall
PMCs in vitro in the presence of inflammatory and anti-inflammatory factors.
We propose that inhibition of Lox in abdominal PMC may help reduce inflammation-asso-
ciated fibrosis and scarring, with implications for the prevention of adhesions following sur-
gery, infection and disease.
Materials and methods
Animals
C57Bl/6 female mice were obtained from Harlan, housed under 12 h light: 12 h dark condi-
tions and given standard rodent chow and water ad libitum. All animal experiments were con-
ducted under a project license approved by the UK Home Office in accordance with the
Targeting lysyl oxidase reduces peritoneal fibrosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183013 August 11, 2017 2 / 19
Animals (Scientific Procedures) Act 1986. Animals used were aged 10–12 weeks at the start of
the experiment. A minimum of 3 and a maximum of 9 mice were used in each experimental
group. Animals were housed in groups, and randomly allocated to each experimental group.
All animals were checked for body condition and overall health on a daily basis by the
experimenter.
Carbon nanotubes (NT)
Multiwalled NT (NTlong2, [19] were obtained from Dr Matthew Boyles, University of Cam-
bridge. NT were prepared for injection by mixing at a concentration of 1 mg/ml with PBS con-
taining 0.5% BSA (PBS-BSA) (Sigma, Poole, Dorset). The suspension was vortexed for 2
minutes followed by sonication in a waterbath containing ice for 15 minutes. This treatment
was repeated for 6 hours after which the suspended NT were stored overnight at 4˚C. Prior to
use the nanotubes were vortexed and sonicated a further 3 times and then diluted with
PBS-BSA to a concentration of 100 μg/ml. Treated mice were injected i.p. with 0.25 ml con-
taining 25 μg NT. Control mice were treated with 0.25 ml PBS-BSA.
BAPN and steroid treatment
The following treatments were given daily starting on the day of NT treatment and continued
for 7 days, unless time was a variable. BAPN (fumarate salt, Sigma) was freshly prepared by
dissolving in PBS-BSA at a concentration of 250 mg/ml. Treated mice were injected i.p with
0.2 ml containing 50 mg BAPN (~ 1 g/kg). Progesterone (Sigma) was prepared as a stock solu-
tion in 100% ethanol at 10 mg/ml. Aqueous suspension was prepared from this stock at a con-
centration of 1 mg/ml. Treated mice were injected i.p with 0.2 ml containing 0.2 mg
progesterone (~10 mg/kg). Dexamethasone (Sigma) was prepared as a stock solution in 100%
ethanol at 10 mg/ml. Aqueous suspension was prepared from this stock at a concentration of
0.1 mg/ml. Treated mice were injected i.p with 0.2 ml containing 0.02 mg dexamethasone (~ 1
mg/kg).
PMC culture
Mesothelial cells were collected and cultured as described previously [20]. Further details are
given in the Supplementary methods (S1 File).
Molecular cloning and lox miRNA-Lentiviral miRNA constructs
Block-It RNAi system (Invitrogen, Life Technologies, Paisley, Renfrewshire) was used to
deliver 21 bp RNAi designed to be specific to mouse LOX variants 1, 2 and 3, which were first
incorporated within a pre-miR based on mouse miR-155 and contained within
pcDNA6.2-GW-emGFP-miR and screened (S1 Fig and S1 Table). The miR-155 creates a stem
loop structure facilitating processing of the RNAi, but specificity is retained to the mRNA tar-
get sequences. In addition, two sequences were identified L-225 and -227 and used in all fur-
ther experiments by first shuttling into pLenti6.2-cppt-CMV-DEST to create pLenti6.2-cppt-
CMV-emGFP-L-225 and -227 and then packaged, using methodology detailed in [21]. Large
scale packaging, titering and production of serum free lentivirus is described previously [22].
Mock transfected, scrambled sequence transfected, and the two most in vitro effective lox
miRNA constructs (225 and 227) (S1 Fig) were prepared in OPTI-MEM medium (Gibco, Life
Technologies, Paisley, Renfrewshire) containing 0.1% polybrene (Sigma). Lentiviral constructs
were used at a dose of 7.0 x 107 TU/injection in 0.5 ml OPTI-MEM. Mice were injected with
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vehicle or vehicle containing miRNA. Two days later animals received a single injection of
25 μg NT (in 0.25 ml PBS/BSA), with one group receiving vehicle alone.
Sample collection—Abdominal wall mesothelial cells
Seven days after NT injection (unless time was a variable), and 24 h after the final vehicle,
BAPN and/or steroid injection, animals were killed by exposure to increasing CO2 concentra-
tions followed by cervical dislocation. Abdominal wall peritoneal mesothelial cells were col-
lected by removing the skin and pinning out the lateral abdominal wall between the hindlimb
and ribcage onto clean foil (S2 Fig). A 1 cm tall section cut from the top of sterile 50 ml Falcon
tube (VWR, Lutterworth, Leicestershire, UK) was placed on the exposed mesothelial surface
and held down firmly. 0.7ml RNA lysis buffer (RNEasy, Qiagen) was placed inside the ring
and the mesothelial surface was scraped for 10–15 seconds using a 1.8 cm wide Costar1 cell
scraper (Corning). The resulting lysate was removed by pipette and stored at -80˚C until
required for RNA extraction. Evidence that this method removed only the mesothelial cells
was obtained by observing cytokeratin staining of tissue that had and had not undergone this
treatment (S3 Fig)
RNA extraction, reverse transcription and quantitative real-time PCR
(qRT–PCR)
RNA was extracted from mesothelial cell lysates using the RNEasy micro extraction kit, with
on column DNAse digestion (Qiagen), following the manufacturer’s instructions. RNA (200
ng) was reverse-transcribed using a High Capacity cDNA Reverse Transcription Kit (Super-
Script1 VILO cDNA Synthesis Kit, Life Technologies), following the manufacturer’s protocol.
Quantification of total transcripts was performed using TaqMan1 Gene Expression Assay (S2
Table) and 18S ribosomal RNA was used for normalization (Life Technologies). qRT–PCR
was performed using the ABI Prism 7600 Sequence Detection System, using TaqMan1 Uni-
versal PCR Master Mix (Life Technologies). Expression was displayed as fold change relative
to the expression level in control animals or 12 h control cell cultures. Primer/probe sets were
pre-validated assay-on-demand reagents (Qiagen). The assay probes all crossed exon bound-
aries. Details of the probes are provided (S2 Table).
Sample collection—Diaphragms
The diaphragms were removed complete with surrounding ribcage (to preserve the tissue
architecture), as described in detail previously [19]. The section of intact ribcage was fixed for
16–24 h using neutral buffered formalin (NBF).
Sample collection—Abdominal wall
A section of abdominal wall (approximately 1cm2) was removed and pinned out with the
mesothelial surface uppermost on a polystyrene block submerged under NBF, where it was
fixed for 16–24 h. This method preserved the structure of the abdominal wall and prevented it
from curling up into a tube.
Histology
Once fixed, a horizontal section of the diaphragm measuring approximately 20 x 3 mm (incor-
porating both the muscular and tendonous regions of the diaphragm) was cut out using a scal-
pel blade and embedded on edge in paraffin wax. The abdominal wall tissue was similarly
embedded on edge. Paraffin embedded sections (5 μm thick) were dewaxed and stained for
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collagen using picrosirius red. The stained sections were tiled to give a complete representation
of the diaphragm section using Media Cybernetics image pro plus software with Stage Pro.
The fibrotic lesion area (mm2) and lesion area stained for collagen per linear mm of diaphragm
were calculated using Adobe Photoshop CS5.1 software.
For details of tissue staining and immunohistochemistry see S1 File.
Electron microscopy
Samples measuring approximately 3 mm x 2 mm (see above) were cut out from the diaphragm
and incubated in glutaraldehyde fixative (2% in 100 mM phosphate buffer, pH 7) for 30 min at
21˚C. Samples were transferred to fresh fixative for 2 hours at 4˚C, and then in fresh glutaral-
dehyde fixative (1% in 50 mM phosphate buffer, pH 6.2) supplemented with 1% osmium
tetroxide for 40 min at 4˚C. Samples were washed in 6 changes of water and transferred to 1%
uranyl acetate for 16 hours at 4˚C. Dehydration was in graded ethanol and embedding in Agar
LV as previously described [23]. Semi-thin (2 μm) sections were placed on a glass slide and
stained with 1% toluidine blue, rinsed in water, and dried on a hot plate. Light microscopy was
used to identify the regions of interest and for tissue orientation. Ultra-thin sections (70 nm)
for transmission electron microscopy were collected using a Leica ultramicrotome and placed
on 200 mesh copper grids. Images were taken using a Tecnai 12 BioTwin electron microscope
operated at 100 kV accelerating voltage.
Statistical analysis
Data are presented throughout as mean ± standard error of the mean (SEM). Statistical analy-
sis was performed using Graphpad Prism 5 software. Comparisons between groups was by
one- or two-way ANOVA, followed by Tukey’s or Benferroni post-hoc testing respectively. A
value of p<0.05 was considered significant for all analyses.
Results
Chemical inhibition of LOX reduces NT-induced fibrosis and collagen
deposition on the diaphragm
Intra-peritoneal injection of NT caused massive accumulation of collagen-rich fibrotic granu-
loma lesions on the abdominal surface of the diaphragm after 7 days, observed using picrosir-
ius red (PSR) staining (Fig 1A, 1B, 1D and 1E). The presence of accumulated NT fibres was
noted (Fig 1E). The granuloma lesions appeared to be on the peritoneal surface, and were asso-
ciated with an accumulation of macrophages and B lymphocytes (S4 Fig). The thickness of the
granuloma lesions and the extent of collagen staining were reduced after 7 days treatment with
BAPN (Fig 1C and 1F). Quantification of granuloma lesion area (Fig 1G) and granuloma
lesion area staining positive for collagen (Fig 1H) showed that BAPN treatment reduced the
effect of NT on both endpoints by 90% (p<0.01)
BAPN causes ultrastructural changes in collagen fibre alignment in the
diaphragm
Transmission electron microscopy revealed ordered collagen fibre bundles lying between the
peritoneal mesothelial cell layer and the muscle layers (Fig 2A and 2D). Note the presence of
typical collagen fibril D-banding striations, with periodicity of 67nm (Fig 2D). NT treatment
increased the amount of collagen present (Fig 2B and 2E). BAPN treatment for 7 days after NT
caused the collagen fibre bundles to lose their ordered arrangement (Fig 2C and 2F).
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Effect of progesterone and dexamethasone on NT-induced fibrosis and
collagen deposition on the diaphragm
Having established that inhibition of Lox activity with BAPN ameliorated the effects of NT on
the diaphragm, we examined if known anti-inflammatory steroids, progesterone and dexa-
methasone were also able to reduce the effects of NT on the diaphragm. We first determined
that the diaphragm mesothelial cells expressed progesterone and glucocorticoid receptor by
immunohistochemistry (S5 Fig). PSR staining revealed that the fibrotic granuloma lesion
Fig 1. BAPN reduces NT-induced fibrosis on the diaphragm. Effect of i.p. treatment with carbon nanotubes (NT, 25 μg) followed by daily
injections for 7 days of the lox inhibitor ß-aminoproprionitrile (BAPN, 1 g/kg) on fibrosis and collagen deposition on the diaphragm. Picrosirius
Red stained sections of control diaphragm treated with PBS (A,D), NT (B,E) and NT+BAPN (C,F). Arrows indicate the thickness of the fibrotic
lesion. Red staining indicates collagen. Fibrotic granuloma lesion area (G) and extent of collagen staining within the lesion (H) were
quantified. Results are expressed as mean ± SEM, n = 3. *, p<0.05; **, p<0.01. One-way ANOVA with Tukey’s multiple comparison post-hoc
testing.
https://doi.org/10.1371/journal.pone.0183013.g001
Fig 2. Electron micrographs of mouse diaphragm showing effect of NT and BAPN on sub-epithelial
collagen deposition. A,D PBS control; B,E 7 days after NT treatment; C,F 7 days after NT plus daily
β-aminopropionitrile (BAPN) treatment. m: mesothelial cells, mu: muscle fibres, l: probable leukocyte.
➔ dense, ordered collagen fibre bundles,⇧ loose, disordered collagen fibres.
https://doi.org/10.1371/journal.pone.0183013.g002
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thickness and collagen content induced by NT injection (Fig 3A and 3B) were reduced by both
progesterone (Fig 3C) and dexamethasone (Fig 3D) treatment for 7 days. Quantification
revealed that granuloma lesion area (Fig 3E) was significantly reduced by both progesterone
(p<0.05) and dexamethasone (p<0.01). Granuloma lesion area staining positive for collagen
Fig 3. Progesterone and dexamethasone reduce NT-induced fibrosis on the diaphragm. Effect of i.p.
treatment with carbon nanotubes (NT, 25 μg) followed by 7 daily injections of PBS (vehicle), progesterone (10 μg) or
dexamethasone (1 μg) on fibrosis and collagen deposition on the diaphragm. Picrosirius Red stained sections of control
diaphragm treated with PBS (A), NT (B), NT + progesterone (C) and NT + dexamethasone (D). Red staining indicates
collagen. Fibrotic granuloma lesion area (E) and extent of collagen staining within the lesion (F) were quantified. Results
are expressed as mean ± SEM, n = 6. *, p<0.05; ***, p<0.001. One-way ANOVA with Tukey’s multiple comparison
post-hoc testing.
https://doi.org/10.1371/journal.pone.0183013.g003
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(Fig 3F) was also reduced by progesterone and dexamethasone, although only the effect of
dexamethasone was statistically significant (p<0.05).
Time dependent effects of NT, progesterone and dexamethasone on
abdominal wall PMC fibrotic gene expression
Practical considerations meant that it was not possible to consistently collect mesothelial cell
mRNA from the diaphragm. However, we were able to consistently collect mRNA from the
PMC on a 6 cm2 section of abdominal wall. To determine if NT treatment induced fibrotic
gene expression in these PMC cells, mRNA was extracted up to 7 days after treatment with
NT. There was a time-dependent increase in both Lox and Col1a1 mRNA expression (p<0.05)
(Fig 4A and 4B). Furthermore, both progesterone (p<0.01) and dexamethasone treatment for
3, 5 and 7 days after NT injection (p<0.001) prevented the NT-induced rise in Lox mRNA
(Fig 4A). A similar effect of progesterone on Col1a1 mRNA (p<0.01 on Day 7) and dexameth-
asone (p<0.001 on Days 5 and 7) was observed (Fig 4B). At all time points dexamethasone was
more effective than progesterone at inhibiting the effect of the NT.
Effect of progesterone, dexamethasone and progesterone plus
dexamethasone on NT-induced fibrotic gene expression in abdominal
wall PMC
Selecting the 7-day time-point after NT injection, we measured the effect of progesterone,
dexamethasone and a combination of these steroids on the expression of Lox, the LOX and
collagen processing enzyme Bmp1, and the collagens Col1a1 and Col3a1 mRNA. In all cases,
NT injection significantly increased mRNA expression (p<0.05), whereas progesterone, dexa-
methasone or the two steroids combined consistently prevented this increase (p<0.05) (Fig 5).
There was no evidence of an additive effect of progesterone and dexamethasone (Fig 5).
Administration of lox miRNA lentiviral constructs reduces abdominal wall
PMC lox mRNA expression in vitro and in vivo and reduces fibrosis on
the diaphragm
To confirm that Lox expression is required for the development of fibrosis in response to NT
treatment, we developed miRNA constructs that target Lox mRNA. Six different lentivral
miRNA constructs transfected into mouse PMC in vitro inhibited Lox mRNA expression
(p<0.001) (S1 Fig). Constructs L-225 and L-227, which target the Lox mRNA variants 1, 2 and
3 at nucleotides 1017 and 1205 bp respectively, but do not target any of the Lox-like mRNA
sequences, inhibited Lox mRNA expression by>90% in vitro, were selected for in vivo use.
Both constructs inhibited NT-induced Lox mRNA expression in PMC in vivo, compared to a
scrambled miRNA sequence (p<0.001) (Fig 6A). Furthermore, both constructs also inhibited
NT-induced fibrotic granuloma lesions (Fig 6B) and fibrotic granuloma lesion area stained for
collagen (Fig 6C) (p<0.05)
Progesterone ameliorates cytokine induced lox mRNA expression by
peritoneal mesothelial cells in vitro
To determine if mouse peritoneal mesothelial cells are responsive to physiological levels of
progesterone, the effect of 1 μM progesterone on IL-1α induced Lox mRNA expression in vitro
was measured for up to 48 h. After both 24 and 48 h, the IL-1α induced expression of Lox was
significantly inhibited by 1μM progesterone (p<0.01 and p<0.001 respectively) (Fig 7). IL-1α
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alone induced Lox expression in a time-dependent manner, although this did not quite reach
statistical significance (p = 0.057) (Fig 7).
Discussion
We have developed a short-term mouse model of peritoneal fibrosis and abdominal wall
fibrotic gene expression that implicates a key role of Lox in peritoneal fibrosis and adhesions.
We have shown that the widely used Lox inhibitor, BAPN, as well as progesterone and dexa-
methasone, reduce NT-induced fibrosis and collagen deposition on the diaphragm. Further-
more, using a novel method to collect PMC mRNA we provide evidence that progesterone
and dexamethasone act by blocking expression of NT-induced Lox and fibrotic genes in PMC,
suggesting a mechanism for anti-fibrotic effects of steroids in the abdominal cavity.
Fig 4. Time-dependent effects of progesterone and dexamethasone on NT-induced fibrotic gene
expression in abdominal wall PMC. Effect of i.p treatment with carbon nanotube (NT, 25 μg) followed by
daily injection for up to 7 days with PBS (vehicle), progesterone (Prog, 10 μg/kg) or dexamethasone (Dex,
1 μg/kg) on Lox (A) and Col1a1 (B) mRNA expression by abdominal wall peritoneal mesothelial cells (PMC) in
vivo. mRNA expression is shown relative to control (day 0 untreated animals) and is the mean ± SEM of 6–8
animals per treatment. a, p<0.05; b, p<0.01 compared with day 0 untreated animals (PBS). *, p<0.05; **,
p<0.01; ***, p<0.001 compared with corresponding treatment with PBS. Two-way ANOVA with Bonferroni
multiple comparison post-hoc testing.
https://doi.org/10.1371/journal.pone.0183013.g004
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The NT-induced fibrosis model [19] exhibited a rapid inflammatory response evidenced by
accumulation of polymorphonuclear leukocytes and protein exudation after 24 h, followed by the
formation of fibrotic granulomatous tissue on the peritoneal surface of the diaphragm, after 7
days. We observed a similar formation of granulomatous collagen-rich fibrotic plaques in our
model, and a 60% inhibition of plaque formation and 90% reduction in collagen content by the
irreversible inhibition of Lox enzyme activity by BAPN. These data suggest a key role of Lox in
the fibrotic response to NT. Electron microscopy showed a sub-epithelial localization of collagen
fibres, increased ordered collagen fibre deposition in response to NT, and disruption of fibre
organization in response to BAPN, similar to the effect of BAPN on collagen lamellar stacking
observed in the cornea [24], confirming a likely role of Lox-regulated collagen cross-linking in
Fig 5. Progesterone and dexamethasone reduce NT-induced fibrotic gene expression in abdominal wall PMC. Effect of i.p
treatment with carbon nanotube (NT, 25 μg) followed by daily injection for 7 days with PBS (vehicle), progesterone (Prog, 10 μg/kg),
dexamethasone (Dex, 1 μg/kg) or Prog+Dex on lox (A), bone morphogenetic protein 1 (Bmp1) (B), Col1a1 (C) and Col3a1 (D) mRNA
expression by abdominal wall peritoneal mesothelial cells in vivo. mRNA expression is shown relative to control day 0 untreated animals
(PBS) and is the mean ± SEM of 8–10 animals per treatment. *, p<0.05; **, p<0.01; ***, p<0.001. One-way ANOVA with Tukey’s multiple
comparison post-hoc testing.
https://doi.org/10.1371/journal.pone.0183013.g005
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Fig 6. Effect of lentiviral lox miRNA construct on carbon nanotube (NT) induced fibrosis on the
abdominal wall and diaphragm. Vehicle, scrambled miRNA and two selected Lox miRNA lentiviral
constructs were injected i.p. followed 2 days later by 25 μg NT (except for the control group which received
vehicle (PBS)). A), Lox mRNA in abdominal wall peritoneal mesothelial cells; B) fibrotic lesion area and C),
extent of collagen staining within the lesion on the diaphragm. *, p<0.05; **, p<0.01; ***, p<0.001. One-way
ANOVA with Tukey’s multiple comparison post-hoc testing.
https://doi.org/10.1371/journal.pone.0183013.g006
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the fibrotic response. C57Bl/6 has previously been identified as a good choice of mouse strain in
which to study peritoneal fibrosis, with this strain exhibiting a significant peritoneal wall thicken-
ing and Col1a2mRNA expression in response to i.p. adenovirus expressing TGFß1 [25].
The probable mechanism of NT-induced changes in the peritoneal mesothelium involves
incomplete phagocytosis of these long NT by recruited macrophages leading to cytokine
release, producing an amplified pro-inflammatory response and further cytokine release by
PMC [26]. IL-1α increases LOX mRNA expression in human OSE (which are morphologically
similar to PMC) in vitro [16,27], but the effect of cytokines on LOX/Lox expression has not
been previously described in human or mouse PMC. Whilst we only occasionally observed
adhesions in the form of liver to diaphragm anastomosis, and abdominal wall of NT treated
mice did not show the regular presence of overt fibrotic plaques or NT deposits, the NT model
has previously been shown to promote formation of intraperitoneal adhesions after 10 weeks
or more of exposure [28]. NT are believed to accumulate on the abdominal surface of the dia-
phragm due to anteriorly directed transport [29,30], which explains the paucity of NT
observed on the abdominal wall.
Macrophages are one of the major cell types contributing to the fibrotic granulomatous tis-
sue on the peritoneal surface of the diaphragm after NT treatment [19 and the present study].
However, the precise role of macrophages in the formation of adhesions is unclear, and they
have alternately been proposed to protect from or promote adhesion formation [31,32]. In a
conditional macrophage ablation mouse model, depletion was associated with the appearance
of abdominal adhesions, although the authors concede that the dimerizer used to induce the
ablation may have caused injury to the mesothelial cells [33].
The mechanism of increased abdominal wall PMC fibrotic gene expression is unclear.
However, we believe that the progressive increases in fibrotic gene expression in abdominal
wall PMC observed in our study represent pre-fibrotic changes that herald the formation of
discreet fibrotic lesions and adhesions in the abdominal cavity, presumably initiated by the
NT-induced leukocytic accumulation [19] and release of inflammatory cytokines [28,34].
Indeed, evidence of a pre-fibrotic response in the abdominal wall PMC was apparent from ele-
vations in Lox, Col1a1 and Col3a1mRNA expression, with NT causing a progressive increase
in abdominal wall Lox and Col1a1 over 7 days. Furthermore, mRNA for Bmp1 encoding
Fig 7. Time dependent effects of IL-1α (2.5 ng/ml and progesterone (Prog) (1 μM) on Lox mRNA
expression by abdominal wall peritoneal mesothelial cells in vitro. mRNA expression is shown relative
to control cultures at 12 h and is the mean ± SEM of 3 separate cultures using cells obtained from 6 mice. **,
p<0.01; ***, p<0.01 compared to corresponding treatment with IL-1α alone. Two-way ANOVA with
Bonferroni multiple comparison post-hoc testing.
https://doi.org/10.1371/journal.pone.0183013.g007
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procollagen C-proteinase type 1 (responsible for both cleavage of the C-terminal propeptide
region of procollagens type I, II and III, as well as for processing of pro-LOX protein to mature
LOX enzyme [35]) is also increased after NT treatment. Our findings are consistent with the
observation of increased Col1a1mRNA expression in mice treated intraperitoneally with
chlorhexidine gluconate and glucose degradation products, which induce a fibrotic response
in the peritoneum [17], and increase COL3A1 mRNA, observed in an in vitro human primary
PMC induced fibrosis study [36].
In addition to stimulating Lox and collagen formation, inflammatory mediators in the peri-
toneal cavity may act through alternative mechanisms to promote adhesions. Clinical and ani-
mal model studies indicate that mesothelial plasminogen activator (PA) activity is reduced
after surgery or laparoscopy, due to reduced tissue (t)PA and increased PA inhibitor (I)
[37,38]. Similarly, in a mouse model of post-inflammatory adhesion formation, CCL1 induced
Pai-1 and inhibited Tpa mRNA expression in peritoneal macrophages, as well as inducing Pai-
1 in PMC cells [39]. Together, this could lead to inhibition of the fibrinolytic pathways that
accompany normal wound healing, and promotion of fibrosis.
To investigate if inhibition of Lox mRNA could reduce fibrosis on the diaphragm, we used
Lox miRNA to knockdown levels of Lox. To our knowledge, this represents the first in vivo
Lox knockdown in the peritoneal cavity. Reduction of NT-induced fibrosis and collagen depo-
sition confirms the importance of PMC Lox synthesis in the development of the fibrotic
response and the deposition of collagen.
Dexamethasone has known anti-inflammatory actions, decreasing vascular permeability and
inhibiting cytokine and chemokine secretion. Animal models showed dexamethasone treat-
ment leads to reduction of pneumoperitoneum-induced adhesion formation in mice [40,41],
peritoneal adhesion formation in rats [42] and surgically-induced adhesion formation in rabbits
[43], although the mechanism remains unclear. Evidence for improvement in adhesion scores
by dexamethasone in randomized controlled clinical trials is conflicting [2]. We clearly demon-
strate that dexamethasone reduces NT-induced expression of Lox, Col1a1,Col3a1 and Bmp1
mRNA in abdominal wall PMC in vivo. GR are present on human PMC cells, and cortisol also
upregulates 11ßHSD1mRNA (and potentially augments its own formation in a positive feed-
back loop)[44]. Whether or not this occurs by a direct effect on the PMC cells in vivo is unclear,
but it could equally involve a reduction in macrophage-generated cytokines.
Progesterone has long been recognised to have anti-inflammatory and immunosuppressive
effects, and was shown to reduce granuloma formation in a subcutaneous fibrosis model in
rats [45]. Peritoneal adhesion formation in a guinea pig fibrosis model was significantly
reduced by i.p. administration of 10 mg/kg progesterone [46]. We show that daily i.p. adminis-
tration of similar doses of progesterone inhibit NT-induced expression of Lox, Col1a1, Col3a1
and Bmp1 mRNA in abdominal wall PMC in vivo.
Intriguingly, LOX activity in the mouse cervix (a collagen rich tissue that undergoes
extensive remodeling) is lowest at dioestrus, and declines throughout pregnancy [47],
inversely proportional to the levels of plasma progesterone, suggesting a possible causal
relationship. Progesterone levels in follicular fluid can reach levels in the 10–100 μM range
in women [48] and mice [49], and the high production rate of progesterone by the corpus
luteum is reflected in progesterone levels 4–5 times higher in peritoneal fluid than in
peripheral plasma [50].
Our observation that 1 μM progesterone suppresses IL1α-induced expression of Lox
mRNA by mouse PMC by in vitro, suggests that the steroid may act directly on PMC to limit
the fibrotic response to inflammatory signals. This concentration of progesterone is similar to
the 175 nM concentration observed in human peritoneal fluid close to the ovary on postovula-
tory day 5 [50]. Furthermore, this suppression of IL-1α induced Lox is reminiscent of a similar
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reduction in cytokine-induced LOX mRNA initiated by cortisol in human OSE cells in vitro
[16]. Further evidence that progesterone could act directly on PMC is demonstrated by the
presence of PR in human PMC [51]. Interestingly, progesterone (1 μM) consistently had simi-
lar anti-inflammatory effects (increasing 11ßHSD1 and reducing COX-2 mRNA) to cortisol on
human PMC in vitro, albeit not significant [51]. Given that periovulatory follicular fluid pro-
gesterone can reach levels 10- to 100-fold higher than this [48], these data support the concept
that progesterone could act to limit fibrosis in the PMC.
A local anti-inflammatory role of cortisol and/or progesterone has been proposed to pro-
vide protection from scarring to the ovarian surface after the wound-like event of ovulation
[44,51]. Thus, locally high levels of both progesterone (in excess of 10 μM) and increases in
both free and total cortisol in human follicular fluid after the LH surge [48] together with cyto-
kine-driven increases in PR and GR expression, and 11ßHSD1 (which preferentially converts
inactive cortisone to active cortisol) in OSE cells [44], provide a mechanism to limit inflamma-
tory responses. The absence of such high levels of steroid in the vicinity of the abdominal PMC
would explain their propensity to undergo fibrotic changes in response to injury. The anatomi-
cal and functional similarity of OSE to PMC would also explain how they might be able to
respond to locally administered anti-inflammatory steroids. Whilst we would favour a direct
action of progesterone and dexamethasone to attenuate Lox expression and subsequent fibro-
sis, our data do not unequivocally demonstrate such a mechanism. Global Lox knockout mice
are embryonic lethal, [52], so further dissection of the mechanisms of these steroid effects
would require a tissue specific conditional Lox knockout in mesothelial cells.
One of the hallmarks of inflammation in mesothelial cells is the onset of epithelial to mesen-
chymal transition (EMT) [25,53] and it is interesting to note in this context that, in a mouse
model of liver fibrosis, PMC covering the liver undergo EMT and differentiate into hepatic
stellate cells and myofibroblasts, leading to submesothelial “capsular” fibrosis”, associated with
increased collagen deposition [54]. Whether this process involves increased expression of LOX
is unknown, but this phenomenon likely implicates Lox in wider aspects of fibrotic disease.
In conclusion, our results provide proof-of-concept that intraperitoneal targeting of Lox
may limit fibrosis and tissue adhesion. Lox-mediated suppression of collagen deposition is
revealed as a key site of anti-inflammatory steroid action. Our findings have broad relevance to
the use of anti-inflammatory agents to prevent adhesion formation following surgery or in asso-
ciation with other debilitating fibrotic conditions such as endometriosis and kidney dialysis.
Supporting information
S1 Fig. LOX mRNA expression in mouse peritoneal mesothelial cells transfected with LOX
miRNA in vitro. Cells were treated for 16 h in serum-free medium containing scrambled
miRNA or 6 different LOX miRNA sequences, followed by 24 h in serum containing medium.
LOX mRNA expression is expressed relative to an untransfected control (No trans). Results
are the mean±SEM of 3 separate cultures using cells obtained from 6 mice. p<0.001 com-
pared with untransfected control.
(TIFF)
S2 Fig. Collection method for mouse abdominal wall peritoneal mesothelial cell mRNA. A,
The lateral wall of the abdominal wall pinned out on clean foil. The linea alba is visible near
the left hand margin. B, Positioning of a 1cm deep section cut from a 50 ml Falcon tube over
the exposed mesothelium. C, Addition of RNA lysis buffer. D) Scraping of the mesothelial sur-
face with cell scraper. E, Removal of lysis buffer.
(TIF)
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S3 Fig. Cytokeratin expression in mouse abdominal wall mesothelial cells without (A,C)
and with (B,D) removal of mesothelial cells using lysis buffer and scraping. Bar = 50 μm.
(TIFF)
S4 Fig. Serial sections of a fibrotic granuloma lesion on the abdominal surface of the dia-
phragm, 7 days after carbon nanotube (NT) treatment. Sections are stained with picrosirius
red (A), cytokeratin (B) and F4/80 (C). NT are clearly visible within the granuloma lesion,
associated accumulations of macrophages (M). A partially intact mesothelial cell layer (PMC)
is visible beneath the granuloma lesion. The granuloma lesion also contains a numerous tightly
packed cells with large nuclei, presumed to be B lymphocytes (BL). Bar = 50 μm.
(TIF)
S5 Fig. Immunohistochemical localization of glucocorticoid receptor (A,C,E,G) and pro-
gesterone receptor (B,D,F,H) in ovarian surface epithelial cells (A,B), abdominal wall
mesothelial cells (C,D) and diaphragm mesothelial cells (E,F). Specific nuclear localisaton is
indicated by the arrows. G,H, uterus positive control (insets are negative control tissue incu-
bated without primary antibody). Bar = 50 μm (A,F) and 100 μm (G,H).
(TIF)
S6 Fig. Fibrotic granuloma lesion on the peritoneal surface of the abdominal wall 7 days
after carbon nanotube (NT) treatment, stained with picrosirius red. NT are clearly visible
within the granuloma lesion. Bar = 50 μm.
(TIF)
S1 Table. Lox RNAi target sequence and location of match in coding region of mouse LOX
variants 1, 2 and 3 (NM_010728.3, 001286181.1 and 001286182.1), counting the start ATG
as nucleotide 1. ^Basepairs (bp), LOX-225 and 1396 were found to be identical and bold italic
font indicates the loop sequences either side of each miRNA construct.
(PDF)
S2 Table. Details of Taqman1 gene expression assays-on-demand.
(PDF)
S1 File. Supplementary materials and methods.
(PDF)
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